Company intelligence / Profile preview

UMN Pharma Inc.

Ownership: Private
Development stage: Commercial

Overview

UMN Pharma has developed a pipeline of recombinant protein-based vaccines targeting major infectious diseases such as influenza and norovirus. The company’s lead candidates include seasonal and pandemic influenza vaccines as well as a multivalent norovirus vaccine designed to cover multiple genotypes. Most programs are in preclinical or pending stages. The company leverages its proprietary BEVS platform for high-yield antigen production and aims to address unmet needs in infectious disease prevention[1][2][5][6].

Therapeutic areas: Metabolic DisordersInfectious Diseases
Modalities: recombinant protein vaccinesprophylactic vaccines
Industry: Biotech

Drug pipeline

2 assets

UMN-0501

1 more asset in the full pipeline.

Request access →

Partnerships

Shionogi & Co., Ltd. – capital and business alliance since October 31st, 2017[5]

Beyond the preview

Go deeper on UMN Pharma Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UMN Pharma Inc..

Explore the full profile